AU2018316811B2 - Modified mRNA vaccines encoding herpes simplex virus glycoproteins and uses thereof - Google Patents

Modified mRNA vaccines encoding herpes simplex virus glycoproteins and uses thereof Download PDF

Info

Publication number
AU2018316811B2
AU2018316811B2 AU2018316811A AU2018316811A AU2018316811B2 AU 2018316811 B2 AU2018316811 B2 AU 2018316811B2 AU 2018316811 A AU2018316811 A AU 2018316811A AU 2018316811 A AU2018316811 A AU 2018316811A AU 2018316811 B2 AU2018316811 B2 AU 2018316811B2
Authority
AU
Australia
Prior art keywords
hsv
another embodiment
present
mrna
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018316811A
Other languages
English (en)
Other versions
AU2018316811A1 (en
Inventor
Sita Awasthi
Gary Cohen
Harvey Friedman
Drew Weissman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania Penn filed Critical University of Pennsylvania Penn
Publication of AU2018316811A1 publication Critical patent/AU2018316811A1/en
Application granted granted Critical
Publication of AU2018316811B2 publication Critical patent/AU2018316811B2/en
Priority to AU2023248194A priority Critical patent/AU2023248194A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2018316811A 2017-08-17 2018-08-17 Modified mRNA vaccines encoding herpes simplex virus glycoproteins and uses thereof Active AU2018316811B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2023248194A AU2023248194A1 (en) 2017-08-17 2023-10-13 Modified MRNA vaccines encoding herpes simplex virus glycoproteins and uses thereof

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762546648P 2017-08-17 2017-08-17
US62/546,648 2017-08-17
US201862701019P 2018-07-20 2018-07-20
US62/701,019 2018-07-20
PCT/IB2018/056210 WO2019035066A1 (en) 2017-08-17 2018-08-17 MODIFIED MHRNA VACCINES ENCODING HERPES SIMPLEX VIRUS GLYCOPROTEINS AND USES THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023248194A Division AU2023248194A1 (en) 2017-08-17 2023-10-13 Modified MRNA vaccines encoding herpes simplex virus glycoproteins and uses thereof

Publications (2)

Publication Number Publication Date
AU2018316811A1 AU2018316811A1 (en) 2020-03-12
AU2018316811B2 true AU2018316811B2 (en) 2023-07-13

Family

ID=65362983

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018316811A Active AU2018316811B2 (en) 2017-08-17 2018-08-17 Modified mRNA vaccines encoding herpes simplex virus glycoproteins and uses thereof
AU2023248194A Pending AU2023248194A1 (en) 2017-08-17 2023-10-13 Modified MRNA vaccines encoding herpes simplex virus glycoproteins and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2023248194A Pending AU2023248194A1 (en) 2017-08-17 2023-10-13 Modified MRNA vaccines encoding herpes simplex virus glycoproteins and uses thereof

Country Status (7)

Country Link
US (3) US11141478B2 (cg-RX-API-DMAC7.html)
EP (2) EP3668520A4 (cg-RX-API-DMAC7.html)
JP (3) JP7386535B2 (cg-RX-API-DMAC7.html)
CN (2) CN118370812A (cg-RX-API-DMAC7.html)
AU (2) AU2018316811B2 (cg-RX-API-DMAC7.html)
CA (1) CA3073161A1 (cg-RX-API-DMAC7.html)
WO (1) WO2019035066A1 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA49463A (fr) * 2017-04-26 2021-05-05 Modernatx Inc Vaccin contre le virus de l'herpès simplex
CA3073161A1 (en) 2017-08-17 2019-02-21 The Trustees Of The University Of Pennsylvania Modified mrna vaccines encoding herpes simplex virus glycoproteins and uses thereof
MA54868A (fr) * 2019-03-12 2021-12-08 BioNTech SE Arn thérapeutique contre le cancer de la prostate
CN111568856B (zh) * 2020-06-24 2021-07-06 珠海舒桐医疗科技有限公司 一种阴道凝胶制剂及其制备方法
US20230256090A1 (en) * 2020-06-29 2023-08-17 Glaxosmithkline Biologicals Sa Adjuvants
US12419948B2 (en) 2020-08-31 2025-09-23 The Broad Institute, Inc. Immunogenic compositions and use thereof
WO2022074358A1 (en) 2020-10-08 2022-04-14 Virokine Therapeutics Limited Vaccine compositions
MX2023008826A (es) 2021-02-01 2023-09-15 Regenxbio Inc Terapia génica para lipofuscinosis neuronal ceroidea.
JP2024512394A (ja) 2021-03-11 2024-03-19 レッドバイオテック・アーゲー Ｈｓｖを処置するためのワクチン組成物及び方法
CN118217388A (zh) * 2022-12-19 2024-06-21 南京奥罗生物科技有限公司 单纯疱疹病毒疫苗及其应用
KR20250137152A (ko) * 2023-01-27 2025-09-17 바이오엔테크 에스이 단순 포진 바이러스 당단백질 c, 당단백질 d, 및 당단백질 e 항원의 전달을 위한 약학적 조성물 및 관련 방법
WO2024163918A1 (en) * 2023-02-02 2024-08-08 University Of Houston System Mrna vaccine for herpes simplex virus
WO2024249967A1 (en) * 2023-06-02 2024-12-05 The Trustees Of The University Of Pennsylvania Rna vaccines encoding herpes simplex virus glycoproteins and uses thereof
WO2025030097A2 (en) * 2023-08-03 2025-02-06 BioNTech SE Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods
WO2025030103A1 (en) 2023-08-03 2025-02-06 The Trustees Of The University Of Pennsylvania Rna compositions encoding herpes simplex virus glycoprotein b antigens and uses thereof
WO2025030165A1 (en) * 2023-08-03 2025-02-06 BioNTech SE Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods
WO2025030134A1 (en) 2023-08-03 2025-02-06 The Trustees Of The University Of Pennsylvania Rna compositions encoding herpes simplex virus glycoprotein e and/or glycoprotein i antigens and uses thereof
WO2025072383A1 (en) 2023-09-25 2025-04-03 The Broad Institute, Inc. Viral open reading frames, uses thereof, and methods of detecting the same
WO2025097055A2 (en) 2023-11-02 2025-05-08 The Broad Institute, Inc. Compositions and methods of use of t cells in immunotherapy
WO2025109008A1 (en) 2023-11-20 2025-05-30 Redbiotec Ag Novel vaccine compositions and methods for treating hsv
WO2025129158A1 (en) 2023-12-15 2025-06-19 The Broad Institute, Inc. Engineered arc delivery vesicles and uses thereof
WO2025175124A1 (en) * 2024-02-15 2025-08-21 Albert Einstein College Of Medicine Recombinant herpes simplex virus glycoprotein b for treatment and prevention of herpes simplex virus infections

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017070623A1 (en) * 2015-10-22 2017-04-27 Modernatx, Inc. Herpes simplex virus vaccine

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
PL2578685T3 (pl) 2005-08-23 2020-01-31 The Trustees Of The University Of Pennsylvania Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania
CA2658484A1 (en) 2006-07-20 2008-01-24 Vical Incorporated Compositions and methods for vaccinating against hsv-2
CN101616688B (zh) * 2006-12-28 2013-12-11 宾夕法尼亚大学理事会 单纯疱疹病毒联合亚单位疫苗及其使用方法
US20130028925A1 (en) 2006-12-28 2013-01-31 Harvey Friedman Herpes simplex virus combined subunit vaccines and methods of use thereof
EP2432504B1 (en) * 2009-05-22 2019-05-01 Genocea Biosciences, Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
CA2816925C (en) 2009-11-04 2023-01-10 The University Of British Columbia Nucleic acid-containing lipid particles and related methods
US9770463B2 (en) * 2010-07-06 2017-09-26 Glaxosmithkline Biologicals Sa Delivery of RNA to different cell types
US9192661B2 (en) * 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
US20130323269A1 (en) 2010-07-30 2013-12-05 Muthiah Manoharan Methods and compositions for delivery of active agents
US9895435B2 (en) * 2012-05-16 2018-02-20 Immune Design Corp. Vaccines for HSV-2
CA2931853C (en) * 2013-12-11 2023-10-03 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Human herpesvirus trimeric glycoprotein b, protein complexes comprising trimeric gb and their use as vaccines
MX365658B (es) * 2014-05-13 2019-06-10 Univ Pennsylvania Composiciones que comprenden virus adenoasociado (aav) que expresa constructos de anticuerpos duales y sus usos.
CN106999572A (zh) * 2014-10-01 2017-08-01 阿德梅杜斯疫苗有限公司 用于诱导对单纯疱疹病毒2型(hsv‑2)的免疫应答的治疗组合物和方法
WO2016176330A1 (en) 2015-04-27 2016-11-03 The Trustees Of The University Of Pennsylvania Nucleoside-modified rna for inducing an adaptive immune response
US10758694B2 (en) 2015-07-09 2020-09-01 Hoyt Medical LLC Systems and methods for treating an airway using a tapered adapter device
EP3364982A4 (en) * 2015-10-22 2019-04-17 ModernaTX, Inc. VACCINES AGAINST SEXUALLY TRANSMITTED DISEASES
US20200163878A1 (en) * 2016-10-26 2020-05-28 Curevac Ag Lipid nanoparticle mrna vaccines
MA49463A (fr) 2017-04-26 2021-05-05 Modernatx Inc Vaccin contre le virus de l'herpès simplex
CA3073161A1 (en) 2017-08-17 2019-02-21 The Trustees Of The University Of Pennsylvania Modified mrna vaccines encoding herpes simplex virus glycoproteins and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017070623A1 (en) * 2015-10-22 2017-04-27 Modernatx, Inc. Herpes simplex virus vaccine

Also Published As

Publication number Publication date
JP2025108645A (ja) 2025-07-23
US20210386853A1 (en) 2021-12-16
US20240024463A1 (en) 2024-01-25
JP2020531465A (ja) 2020-11-05
EP3668520A4 (en) 2021-05-12
AU2023248194A1 (en) 2023-11-02
EP3668520A1 (en) 2020-06-24
EP4242223A3 (en) 2024-03-13
JP7386535B2 (ja) 2023-11-27
JP7674760B2 (ja) 2025-05-12
EP4242223A2 (en) 2023-09-13
CA3073161A1 (en) 2019-02-21
CN118370812A (zh) 2024-07-23
US20200276300A1 (en) 2020-09-03
US11141478B2 (en) 2021-10-12
AU2018316811A1 (en) 2020-03-12
CN111246854A (zh) 2020-06-05
JP2023153423A (ja) 2023-10-17
US11793872B2 (en) 2023-10-24
WO2019035066A1 (en) 2019-02-21

Similar Documents

Publication Publication Date Title
US11793872B2 (en) Modified MRNA vaccines encoding herpes simplex virus glycoproteins and uses thereof
US11510977B2 (en) Nucleic acid vaccines for coronavirus
JP7330590B2 (ja) 水痘帯状疱疹ウイルス（ｖｚｖ）のための核酸ワクチン
US10695419B2 (en) Human cytomegalovirus vaccine
EP4444345A2 (en) Herpes simplex virus mrna vaccines
WO2023006062A1 (en) Nucleic acid vaccines for mutant coronavirus
HK40100925A (en) Modified mrna vaccines encoding herpes simplex virus glycoproteins and uses thereof
US20240016922A1 (en) Rna vaccines encoding herpes simplex virus glycoproteins and uses thereof
CN120379690A (zh) 基于核酸的通用疫苗和其使用方法
WO2025030134A1 (en) Rna compositions encoding herpes simplex virus glycoprotein e and/or glycoprotein i antigens and uses thereof
WO2025212831A1 (en) Methods of inducing an anti-hsv b-cell immune response
WO2025030103A1 (en) Rna compositions encoding herpes simplex virus glycoprotein b antigens and uses thereof
WO2024249967A1 (en) Rna vaccines encoding herpes simplex virus glycoproteins and uses thereof
WO2024245317A9 (en) Mutated fragment of vzv glycoprotein e
WO2024163918A1 (en) Mrna vaccine for herpes simplex virus
WO2025255393A1 (en) Herpes simplex virus antigen binding agents for mitigation of herpes simplex virus associated disease

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)